Iproteos has closed a funding round of 1.5M €, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech Ascil Biopharm.
The funding will cover the preclinical drug development of Iproteos’ candidate for Cognitive Impairment Associated with Schizophrenia (CIAS) treatment. Iproteos will perform afterwards phase I and will license out the drug after Phase IIa.
Currently there is no treatment for CIAS, a condition that provokes memory impairment and hinders the daily life of patients. The drugs in development pursue already explored mechanisms of action, while Iproteos target is novel, fact that adds value to the biotech project.
Iproteos is glad to welcome Caixa Capital Risc, Kinled and Ascil Biopharm to the team!
For the complete Press release: Ndp Iproteos-Ronda 1.5M€_ eng.pdf
PARA LEER LA NOTA DE PRENSA EN CASTELLANO: Ndp Iproteos-Ronda 1.5M€_ cast.pdf